Patents Examined by Larry D Riggs, II
  • Patent number: 11174288
    Abstract: Disclosed are peptides comprising an amphiphilic backbone and a cationic heparin-binding motif peptide. The peptides can be used in methods of antimicrobial treatment.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: November 16, 2021
    Assignee: Northeastern University
    Inventors: Run Chang, Keerthana Subramanian, Mian Wang, Thomas J. Webster
  • Patent number: 11154590
    Abstract: An Nkx3.2 fragment with improved stability under a histopathological environment of arthritis and a pharmaceutical composition containing the Nkx3.2 as an active ingredient are disclosed. The Nkx3.2 fragment has a function to activate NF-?B at the similar level to full-length Nkx3.2 and resistance to proteolysis by Siah1. In addition, the Nkx3.2 fragment exhibited at least a 10-fold improvement in degenerative arthritis treatment effect compared with Nkx3.2 in an animal model-based in vivo efficacy evaluation. Therefore, the Nkx3.2 fragment can be favorably used in the prevention or treatment of arthritis.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: October 26, 2021
    Assignee: ICM CO., LTD.
    Inventor: Dae-Won Kim
  • Patent number: 11058719
    Abstract: A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a nutritional supplements composition for treating a subject with complications resulting from sickle cell anemia. The method comprises administering to a subject an effective amount of the nutritional supplement.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: July 13, 2021
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Jacqueline Hibbert, Jonathan K. Stiles, Kayellen Umeakunne, Hyacinth I. Hyacinth
  • Patent number: 10993988
    Abstract: The present invention relates to a veterinary composition comprising an effective amount of at least one cyclic depsipeptide and at least one macrocyclic lactone; and a pharmaceutically acceptable carrier, for the treatment or prophylaxis of parasitic infection in a mammal wherein the parasite shows resistance to treatment or prophylaxis with the macrocyclic lactone alone.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: May 4, 2021
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Brenda Bondesen, Lance Hammerland
  • Patent number: 10987408
    Abstract: A method of promoting hair growth of a subject includes administering to follicle cells of the subject a therapeutically effective amount of a TLR2 agonist that promotes TLR2 activation and hair growth of the subject.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: April 27, 2021
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventor: Tatiana Byzova
  • Patent number: 10968442
    Abstract: Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods for making chimeric clotting factors and methods for improving hemostasis using these clotting factors.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 6, 2021
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Joe Salas, Robert Peters, Alan Bitonti
  • Patent number: 10967000
    Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising amino acid sequence of SEQ ID NO:1, a fragment of any one sequence of SEQ ID NO:1, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: April 6, 2021
    Assignee: Gemvax & Kael Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 10953104
    Abstract: Disclosed are peptide conjugates comprising an active agent, a spacer moiety, and a dimeric collagen hybridizing peptide comprising a first and second collagen hybridizing peptide, a linker; and a branch point, wherein the first and second collagen hybridizing peptides comprise the sequence of at least (GXY)n, wherein G is glycine, wherein X and Y are any amino acid, and wherein n is any number between 3 and 12. Also disclosed are methods of detecting denatured collagen in a sample comprising contacting a composition comprising any one of the disclosed peptide conjugates to a sample, wherein the active agent comprises a therapeutic agent, and detecting the presence or absence of binding of the peptide conjugate to denatured collagen, the presence of binding indicating the presence of denatured collagen in the sample.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: March 23, 2021
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Julian Kessler, Michael S. Yu, Yang Li
  • Patent number: 10954287
    Abstract: The present invention provides Ras modulators including inhibitors and/or antagonists of Ras, Ras binding, and Ras-dependent cell signaling activity. Also provided are methods of utilizing the Ras modulators as therapeutics.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: March 23, 2021
    Assignee: RA PHARMACEUTICALS, INC.
    Inventors: Kristopher Josephson, Zhong Ma, Yili Sun, Nathan Ezekiel Nims, Kathleen Seyb, Sylvia Tobe, Ping Ye, Douangsone D. Vadysirisack, Guo-Qing Tang, Douglas A. Treco
  • Patent number: 10947539
    Abstract: Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: March 16, 2021
    Inventors: Bruce H. Littman, John F. Thompson, Frank W. Marcoux
  • Patent number: 10941187
    Abstract: The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: March 9, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Nigel H. Greig, Josephine M. Egan, Maire Doyle, Harold W. Holloway, Tracy Perry
  • Patent number: 10934341
    Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: March 2, 2021
    Assignee: ALBUMEDIX, LTD.
    Inventors: Jason Cameron, Karen Ann Delahay, Jens Erik Nielsen, Andrew Plumridge, Jan Terje Andersen
  • Patent number: 10927147
    Abstract: The invention relates to novel Muramyl Dipeptide (MDP) derivative compound of structural Formula-VIII, a process for synthesis, intermediates used in the synthesis and use thereof. Wherein, R can be both linear and branched alkyl, aryl, substituted aryl and alkoxy alkyl. These compounds possess excellent pharmacological properties, in particular immunomodulating properties for use as adjuvant in vaccine formulations. These compounds are, particularly useful as adjuvants in vaccines.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: February 23, 2021
    Assignees: Bharat Biotech International Limited, Council of Scientific and Industrial Research
    Inventors: Krishna Murthy Ella, Ganneru Brunda, Halmathur Mahabalarao Sampath Kumar, Miryala Sreekanth
  • Patent number: 10921324
    Abstract: Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: February 16, 2021
    Assignee: AELAN CELL TECHNOLOGIES, INC.
    Inventors: Victoria Lunyak, James Robert Tollervey
  • Patent number: 10919936
    Abstract: The present invention provides stapled polypeptides of the Formulae (I) and (VI): and salts thereof; wherein the groups ; R1a, R1b, R1c, R2a, R3a, R2b, R3b, R4a, R4b, RA, RZ, L1a, L1b, L2, L3, XAA, v, w, p, m, s, n, t, and q are as defined herein. The present invention further provides methods of preparing the inventive stapled polypeptides from unstapled polypeptide precursors. The present invention further provides pharmaceutical compositions comprising a stapled polypeptide of Formula (I) or (VI), and methods of using the stapled peptides. The present invention also provides modifications of the staples post ring closing metathesis.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: February 16, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: Gregory L. Verdine, Gerard Hilinski
  • Patent number: 10918104
    Abstract: Disclosed are peptides that induce an active plant response, but not a hypersensitive response, when applied to plant tissue. These peptides also preferably exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post-harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: February 16, 2021
    Assignee: PLANT HEALTH CARE, INC.
    Inventors: Zhongmin Wei, Gregory A. Zornetzer
  • Patent number: 10894074
    Abstract: A synergistic, multi-factor hair growth formulation and its method of use are described. A plurality of synthetic peptides and proteins are selected to maximize efficacy at discrete stages of the anagenic growth phase of a hair follicle, and these compounds may be further coated to promote uptake into the skin and/or hair root. The formulation itself is topical, so as to allow for direct, selective application alone or in combination with mechanical or energetic delivery techniques.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: January 19, 2021
    Assignee: SKINQRI, LLC
    Inventor: James Bartholomeusz
  • Patent number: 10894009
    Abstract: The present invention aims to provide a cyclosporine external preparation showing improved transdermal absorbability of cyclosporine. The present invention provides an external preparation containing cyclosporine and a ketone.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: January 19, 2021
    Assignee: MARUHO CO., LTD.
    Inventors: Hiroki Sakiyama, Noriaki Kaneda, Tomomi Shigeno
  • Patent number: 10894808
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are specific for the human and rat protease plasma kallikrein and are modified in one or two peptide loops to enhance potency and/or protease resistance.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: January 19, 2021
    Assignee: BicycleRD Limited
    Inventors: Daniel Teufel, Catherine Stace, Edward Walker
  • Patent number: 10865334
    Abstract: The invention is directed to a process for extracting materials from biological material, which process is characterized in that the naturally occurring biological material is treated with an extractant consisting of a deep eutectic solvent of natural origin or a an ionic liquid of natural origin to produce a biological extract of natural origin dissolved in the said solvent or ionic liquid.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: December 15, 2020
    Assignee: Universiteit Leiden
    Inventors: Jacob van Spronsen, Geert-Jan Witkamp, Frank Hollman, Young Hae Choi, Robert Verpoorte